You are viewing the site in preview mode

Skip to main content

Advertisement

Fig. 5 (abstract P166). | Journal for ImmunoTherapy of Cancer

Fig. 5 (abstract P166).

From: 32nd Annual Meeting and Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2017): Part One

Fig. 5 (abstract P166).

Adoptive transfer of TCR-transduced T cells but not mock-transduced T cells results in inhibition of intracranial H3.3K27M+ glioma in NSG mice. NSG mice bearing intracranial U87H3.3K27M luciferase+ gliomas received intravenous infusion with PBS, mock-transduced T cells or TCR-transduced T cells. A. Tumor growth is presented as radiance (107 p/s/cm2/r) using BLI (n=8 per group). Arrows indicate days on which mice received treatment. B. Representative BLI images of mice on Day10 and on Day 32 post tumor inoculation. The background BLI signals were defined based on the levels seen in non-tumor bearing mice. C. Preferential accumulation of TCR+ T cells in the tumor site. At the time of intravenous infusion, approximately 50% and 30% of the infused CD8+ and CD4+ T cells, respectively, were TCR-Dextramer+. On Day 2 following second intravenous infusion, the percentage of Dextramer+ cells among CD8+ T cells and CD4+ T cells were evaluated in the peripheral blood and the brain of mice that received TCR-transduced T cells. Data indicate % Dextramer+ cells among total live CD8+ or CD4+ T cells (n=5 per group). *p

Back to article page